A study suggests that recalling past alcohol experiences before drinking can slow down consumption, indicating a potential strategy to reduce alcohol intake. In the study, women who remembered a previous drinking episode took longer to consume an alcoholic beverage, possibly due to reduced motivation to drink. This approach, along with strong health warnings, may offer new methods to curb excessive alcohol consumption. Further research is needed to explore this effect in males.

Two New Proteins Linked to ALS
https://neurosciencenews.com/als-proteins-genetics-27575/

A new study identifies two proteins that interact with a mutant FUS variant linked to familial ALS, offering a potential therapeutic target. Researchers found that inhibiting these proteins in motor neurons derived from human stem cells reduced ALS-related changes. The findings suggest that similar mechanisms may be involved in sporadic ALS, which affects most patients. Further research will explore these proteins' roles in other ALS-related genes and sporadic cases.

Knowingly Taking Placebos Reduces Stress and Anxiety
https://neurosciencenews.com/placebo-stress-anxiety-27576/

Researchers have discovered that nondeceptive placebos—placebos given with the full knowledge that they are placebos—can effectively manage stress, even when administered remotely. In a two-week randomized controlled trial, participants experiencing prolonged stress were divided into two groups: one group received nondeceptive placebos, while the other served as a control.

Does Multiple Sclerosis Lower Dementia Risk?
https://neurosciencenews.com/multiple-sclerosis-dementia-27577/

Research has revealed that individuals with multiple sclerosis (MS) are significantly less likely to exhibit the molecular signs of Alzheimer’s disease, suggesting a protective element in MS that could inspire new Alzheimer's treatments. The study found that MS patients had 50% less amyloid plaque accumulation, a key indicator of Alzheimer’s, compared to non-MS individuals. This connection between MS and reduced Alzheimer's risk highlights potential immune-related mechanisms that may be leveraged for therapeutic strategies.

Two New Proteins Linked to ALS
https://neurosciencenews.com/als-proteins-genetics-27575/

A new study identifies two proteins that interact with a mutant FUS variant linked to familial ALS, offering a potential therapeutic target. Researchers found that inhibiting these proteins in motor neurons derived from human stem cells reduced ALS-related changes. The findings suggest that similar mechanisms may be involved in sporadic ALS, which affects most patients. Further research will explore these proteins' roles in other ALS-related genes and sporadic cases.

Knowingly Taking Placebos Reduces Stress and Anxiety
https://neurosciencenews.com/placebo-stress-anxiety-27576/

Researchers have discovered that nondeceptive placebos—placebos given with the full knowledge that they are placebos—can effectively manage stress, even when administered remotely. In a two-week randomized controlled trial, participants experiencing prolonged stress were divided into two groups: one group received nondeceptive placebos, while the other served as a control.

Does Multiple Sclerosis Lower Dementia Risk?
https://neurosciencenews.com/multiple-sclerosis-dementia-27577/

Research has revealed that individuals with multiple sclerosis (MS) are significantly less likely to exhibit the molecular signs of Alzheimer’s disease, suggesting a protective element in MS that could inspire new Alzheimer's treatments. The study found that MS patients had 50% less amyloid plaque accumulation, a key indicator of Alzheimer’s, compared to non-MS individuals. This connection between MS and reduced Alzheimer's risk highlights potential immune-related mechanisms that may be leveraged for therapeutic strategies.